Azitra (AZTR) Gains from Investment Securities (2022 - 2025)
Azitra's (AZTR) quarterly Gains from Investment Securities came in at -$51.0 in Q4 2025, up 32.89% YoY from -$38.38 in Q4 2024, and up 61.65% on a QoQ basis from -$133.0 in Q3 2025.
Azitra (AZTR) Gains from Investment Securities (2022 - 2025) Analysis & Trends
Azitra (AZTR) has 4 years of Gains from Investment Securities data on file, last reported at -$51.0 in Q4 2025.
- Quarterly Gains from Investment Securities rose 32.89% year-over-year to -$51.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$238.0 (up 99.99% YoY) and the FY2025 annual result came in at -$381.0, up 99.99% from the prior year.
- Gains from Investment Securities rose to -$51.0 in Q4 2025, from -$133.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $94036.0 in Q2 2023 to a low of -$4.0 million in Q3 2024.
- A 4-year average of -$290719.2 and a median of -$393.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 25293.51% — and 2025, when it jumped 100.0%.
- Tracing AZTR's Gains from Investment Securities over 4 years: stood at -$401.0 in 2022, then plunged by 6254.11% to -$25480.0 in 2023, then jumped by 99.7% to -$76.0 in 2024, then jumped by 32.89% to -$51.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$51.0 (Q4 2025), -$133.0 (Q3 2025), and -$54.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -51.00 |
| Dec 31, 2025 | -51.00 |
| Sep 30, 2025 | -133.00 |
| Sep 30, 2025 | -133.00 |
| Jun 30, 2025 | -54.00 |
| Jun 30, 2025 | -54.00 |
| Mar 31, 2025 | -143.00 |
| Mar 31, 2025 | -143.00 |
| Dec 31, 2024 | -76.00 |
| Dec 31, 2024 | -76.00 |
| Sep 30, 2024 | -4.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Jun 30, 2024 | -4,372.00 |
| Jun 30, 2024 | -4,372.00 |
| Mar 31, 2024 | -28,155.00 |
| Mar 31, 2024 | -28,155.00 |
| Dec 31, 2023 | -25,480.00 |
| Dec 31, 2023 | -25,480.00 |
| Sep 30, 2023 | -97,765.00 |
| Sep 30, 2023 | -97,765.00 |